Acumen Pharmaceuticals (ABOS) has provided an announcement.
Acumen Pharm recently updated its corporate presentation, available on its investor relations website, to highlight the anticipated timeline for topline data from its Phase 1 trial of sabirnetug and to provide current details on its financial standing as of June 30, 2024. This updated presentation is now a part of the company’s public communications strategy, although it’s specified that this information is not deemed legally “filed” nor does it imply any materiality under financial disclosure regulations.
See more data about ABOS stock on TipRanks’ Stock Analysis page.
